HTRA2 and essential thrombocythemia: Individuals heterozygous for HTRA2 p.G399S presented ET symptoms typically after the age of 70, whereas homozygous carriers developed ET with earlier onset and more severe postural and kinetic tremors and additionally manifested Parkinsonian features in middle age.